Shares of medical device company DexCom (NASDAQ:DXCM) jumped 7.3% in the morning session after it reported ...

DexCom has underperformed the Nasdaq Composite over the past year, yet analysts remain highly optimistic about the stock’s future.

What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected ...

One underappreciated reason why I feel DXCM could potentially gain more favorable interest is because its long-suffering ...

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...

But what if companies outside of the pharmaceutical industry benefit as well? One excellent candidate to do so is DexCom ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...

DexCom (NASDAQ: DXCM) has outperformed the market over the past 10 years by 2.92% on an annualized basis producing an average annual return of 16.14%. Currently, DexCom has a market capitalization of ...

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

Shares of DexCom Inc. DXCM slipped 3.03% to $70.69 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.56% to 6,830.71 and Dow ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...